Ten databases will be searched to identify appropriate literature: MEDLINE, the Cochrane Central Register of Controlled Trials, EMBASE, CINAHL, PsycINFO, LILACS, OpenSIGLE, the Chinese Biomedical Literature Database, the Chinese Medical Current Contents and the Chinese National Knowledge Infrastructure. All randomised controlled trials that meet our inclusion criteria will be included. The primary outcome will be QoL as evaluated by self-reported measures. The secondary outcomes will be self-reported or objectively measured psychological outcomes, including anxiety and depression. Review Manager V.5.3 will be used to synthesise the data, calculate treatment effects, perform any subgroup analyses and assess the risk of bias in included studies.
The results will be presented at international conferences and published in peer-reviewed journals. As no individual data will be involved in this review, ethical approval is not required.
方法:将搜索十个数据库以确定适当的文献:MEDLINE,Cochrane中央受控试验登记册,EMBASE,CINAHL,PsycINFO,LILACS,OpenSIGLE,中国生物医学文献数据库,中国医学现状与中国国家知识基础设施。所有符合我们纳入标准的随机对照试验都将被纳入。主要结果将是通过自我报告措施评估的QoL。次要结果将是自我报告或客观测量的心理结果,包括焦虑和抑郁.ReviewManagerV.5.3将用于合成数据,计算治疗效果,在纳入研究中进行亚组分析并评估偏倚风险.
背景:结果将在国际会议上发表,并在同行评审的期刊上发表。由于本次审查将不涉及任何个人数据,不需要道德批准。